Therefore, currently a genetic test for MYC rearrangement and, if positive, for BCL2 and BCL6, is required for DLBCL patients for diagnosis, prognosis, and to guide therapy. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.